Phio Pharmaceuticals (PHIO) said Wednesday the Safety Monitoring Committee has recommended dose escalation in its phase 1b clinical trial of PH-762 as a potential neoadjuvant treatment for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.
The recommendation came after seven patients in the study with cutaneous carcinoma showed at least 90% tumor clearance after 36 days, the company said.
Shares of the biotech firm were up more than 20% in recent premarket activity Wednesday.
Price: 1.22, Change: +0.21, Percent Change: +20.76
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。